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Decreased miR‑200b‑3p in cancer 
cells leads to angiogenesis in HCC 
by enhancing endothelial ERG 
expression
Aye Moh‑Moh‑Aung1, Masayoshi Fujisawa1, Sachio Ito2, Hiroshi Katayama2, Toshiaki Ohara1, 
Yoko Ota1, Teizo Yoshimura1 & Akihiro Matsukawa1*
Transcription factor ERG (erythroblast transformation‑specific (ETS)‑related gene) is essential in 
endothelial differentiation and angiogenesis, in which microRNA (miR)‑200b‑3p targeting site is 
expected by miRNA target prediction database. miR‑200b is known decreased in hepatocellular 
carcinoma (HCC), however, the functional relation between ERG and miR‑200b‑3p, originating from 
pre‑miR‑200b, in HCC angiogenesis remains unclear. We investigated whether hepatocyte‑derived 
miR‑200b‑3p governs angiogenesis in HCC by targeting endothelial ERG. Levels of miR‑200b‑3p in HCC 
tissues were significantly lower than those in adjacent non‑HCC tissues. Poorly differentiated HCC cell 
line expressed lower level of miR‑200b‑3p compared to well‑differentiated HCC cell lines. The numbers 
of ERG‑positive endothelial cells were higher in HCC tissues than in adjacent non‑HCC tissues. There 
was a negative correlation between the number of ERG‑positive cells and miR‑200b‑3p expression 
in HCC tissues. Culture supernatants of HCC cell lines with miR‑200b‑3p‑overexpression reduced cell 
migration, proliferation and tube forming capacity in endothelial cells relative to the control, while 
those with miR‑200b‑3p‑inhibition augmented the responses. Exosomes isolated from HCC culture 
supernatants with miR‑200b‑3p overexpression suppressed endothelial ERG expression. These results 
suggest that exosomal miR‑200b‑3p from hepatocytes suppresses endothelial ERG expression, and 
decreased miR‑200b‑3p in cancer cells promotes angiogenesis in HCC tissues by enhancing endothelial 
ERG expression.
Globally, hepatocellular carcinoma (HCC) is one of the main causes of cancer-related  death1. Similar to other 
cancers, angiogenesis is essential for cancer growth and metastasis in HCC. An angiogenic switch is always 
activated within tumors, which results in vascular  hyperplasia2. Activation of angiogenic switches is regulated by 
various factors elicited by tumor cells or tumor  microenvironments3. Recently, there is an increasing interest in 
understanding the tumor angiogenesis process as regulating angiogenesis is a potential target for cancer therapy.
In recent decades, there is a renewed interest in evaluating the roles of microRNAs (miRNAs) in cancer 
biology. miRNAs are small (18–22 nucleotides) non-coding RNA molecules, which modulate various cellular 
activities, such as proliferation, differentiation, apoptosis, and  angiogenesis4,5. miRNAs regulate angiogenesis by 
targeting angiogenic factors and protein  kinases6. Despite aberrant miRNAs expressions in  HCC7, it is worthy 
to note that miR-200b is down-regulated in HCC tissues as compared to adjacent non-cancer  tissues8. Recent 
studies demonstrated that miR-200b suppresses angiogenesis. Downregulation of endothelial miR-200b promotes 
the cutaneous wound  angiogenesis9. miR-200b inhibits angiogenesis through direct and indirect mechanisms by 
targeting interleukin-8 and CXCL1 by tumor endothelial and cancer  cells10. miR-200b silences several angiogenic 
growth factors and their receptors by directly targeting their mRNA  transcripts11.
A detailed investigation on the role of miR-200b in angiogenesis is important to elucidate the pathological 
mechanism underlying HCC. Each miRNA regulates hundreds of genes, which can be predicted by miRNA 
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target prediction database. Recently, miRNAs are known to target ERG (erythroblast transformation-specific 
(ETS)-related gene) in prostate cancer and colorectal  cancer12,13. ERG plays an essential role in endothelial 
homeostasis, differentiation, and  angiogenesis14,15, in which miR-200b-3p targeting site is expected by miRNA 
target prediction database. We hypothesized that down-regulated miR-200b-3p in HCC may cause enhanced 
endothelial ERG expression, leading to increased angiogenesis in the cancer microenvironment.
In this study, we, for the first time, demonstrate that ERG is a target of miR200b-3p and hepatocyte-derived 
miR-200b-3p reduces the endothelial cell migration, proliferation and tube forming capacity in endothelial 
cells. Additionally, we demonstrate that HCC tissues exhibit reduced miR-200b-3p expression, which causes 
augmented endothelial ERG expression, promoting angiogenesis in the cancer microenvironment. Furthermore, 
miR-200b-3p appears to be transferred by exosomes released from hepatocytes. Thus, miR-200b-3p can be a 
novel therapeutic target for the regulation of cancer angiogenesis.
Results
Expression of miR‑200b‑3p in HCC tissues and cell lines. The expression levels of miR-200b-3p were 
analyzed in forty pairs of clinical HCC and adjacent non-cancer tissues by qRT-PCR. The cases for the enrolled 
40 patients with HCC are shown in Table 1. As shown in Fig. 1a, the miR-200b-3p expression levels in the HCC 
tissues were significantly lower than those in adjacent non-cancer tissues. The miR-200b-3p expression levels 
tended to be lower with decreasing grade of cancer differentiation although it was not statistically significant 
(Fig. 1b). Further detailed clinical data from enrolled patients with HCC were shown in Table 2. Among HCC 
with trabecular pattern, miR-200b-3p expression levels in moderately plus poorly differentiated HCC tended 
to be lower than those in well differentiated HCC (Table 2). Next, we examined the expression levels of miR-
200b-3p in three HCC cell lines. The expression levels of miR-200b-3p in poorly differentiated cell line (HLE 
cell) were significantly lower than those in two well-differentiated HCC cell lines (Hep3B and HepG2 cells) 
(Fig. 1c). In contrast, the expression levels of miR-200b-3p in HUVECs was extremely low when compared to 
those in three HCC cell lines (Fig. 1c). These data indicate that non-cancer tissues, likely non-cancer hepato-
cytes, exhibit high levels of miR-200b-3p expression, whereas HCC tissues, likely cancer cells, exhibit decreased 
expression depending on the degree of cancer differentiation.
Expression of ERG in HCC tissues. Expression of ERG in HCC tissues was next analyzed. As shown in 
Fig. 2a, nuclei of endothelial cells in tissue samples were stained positive for ERG. The numbers of ERG-positive 
endothelial cells in cancer tissue were more than those in adjacent non-cancer tissue (Fig. 2b). As shown in 
Fig. 2c, the statistical analysis indicated a negative correlation between the number of ERG-positive endothelial 
cells and the expression of miR-200b-3p in the HCC tissues (r = − 0.4836, p < 0.0001), suggesting that decreased 
miR-200b-3p expression in cancer tissue causes vascular hyperplasia in HCC tissues.
miR‑200b‑3p negatively regulates endothelial ERG expression. ERG is a transcription factor, and 
plays a crucial rule in vascular development, angiogenesis and vascular  stability14–16. We assumed that miR-
200b-3p may affect endothelial ERG expression. To investigate this assumption, miR-200b-3p was overexpressed 
in HUVECs, after which the cells were cultured with complete medium containing VEGF, and the ERG expres-
sion was examined by western blotting. As shown in Fig. 3a, levels of ERG in HUVECs overexpressing miR-
200b-3p were significantly lower than those in controls. Although HUVECs exhibited much lower miR-200b-3p 
expression levels compared to HCC cell lines (Fig. 1c), inhibition of miR-200b-3p in HUVECs increased the 
ERG expression when compared to controls (Fig. 3b). These data show that miR-200b-3p partly downregulates 
endothelial ERG expression.
ERG is a direct target of miR‑200b‑3p. Analyzing the microRNA target prediction database and tools, 
such as TargetScanHuman (https ://www.targe tscan .org/vert_72/), microRNA.org (https ://www.micro rna.org/
micro rna/home.do) and miRDB (https ://mirdb .org) revealed that the seed region of miR-200b-3p and 3′-UTR 
of ERG mRNA (position 624–631) are complementary (Fig. 4a). We generated an oligonucleotide of 23 base 
pairs containing miR-200b-3p binding sequence of ERG 3′-UTR and cloned into pmirGLO Dual-Luciferase 
miRNA Target Expression Vector and analyzed if ERG is a direct target of miR-200b-3p by using the dual-lucif-
erase reporter assay. A similar construct lacking the target sequence of 3′-UTR of ERG was used as mutant con-
struct. As shown in Fig. 4b, co-expression of precursor miRNA-200b-3p and wild type ERG 3′-UTR construct in 
HEK239T cells significantly reduced luciferase activity. There was no significant difference in luciferase activities 
when the ERG 3′-UTR sequence was mutated (p = 0.1686) (Fig. 4b). These data indicate that miR-200b-3p can 
directly target the 3′-UTR of the ERG gene and suppress the ERG expression.
Hepatic miR‑200b‑3p suppresses endothelial ERG expression. To examine the relation between 
hepatic miR-200b-3p and endothelial ERG, HUVECs were cultured with two types of HCC culture superna-
tants. For gain-of-function analysis, we overexpressed miR-200b-3p in HLE cells (miR-200b-3p expression; low, 
Fig. 1c) and harvested culture supernatants at 48 h (Fig. 5a). For loss-of-function experiments, we treated Hep3B 
cells (miR-200b-3p expression; high, Fig. 1c) with a specific inhibitor or inhibitor control and harvested cul-
ture supernatants (Fig. 5b). The culture supernatants were mixed with complete medium at a ratio of 1:1, and 
the HUVECs were cultured. As shown in Fig. 5c, the protein expression levels of ERG in HUVECs cultured 
with miR-200b-3p overexpression supernatants were lower than those with the control. By contrast, the pro-
tein expression levels of ERG in HUVECs treated with culture supernatants of miR-200b-3p-inhibition were 
higher than those with control (Fig.  5d). This suggests that hepatocyte-derived miR-200b-3p downregulates 
ERG expression in HUVECs.
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Hepatic miR‑200b‑3p inhibits angiogenesis. Angiogenesis requires not only endothelial cell prolifera-
tion but also their migration and formation of tubes. Scratch wound healing assay was performed using HUVECs 
to examine the role of miR-200b-3p in endothelial cell migration. Culture supernatants with miR-200b-3p over-
expression inhibited the closure of HUVECs when compared to control (Fig. 6a, upper). In contrast, culture 
supernatants with miR-200b-3p-inhibition accelerated the wound closure (Fig. 6a, lower). miR-200b-3p-over-
expressing culture supernatants decreased the proliferation of HUVECs (Fig. 6b, upper), which was increased by 
culture supernatants with miR-200b-3p-inhibition (Fig. 6b, lower). Next, tube formation assay was performed 
to evaluate the ability of HUVECs to form capillary-like structures. HUVECs cultured with miR-200b-3p-over-
expressing supernatants exhibited reduced capacity to form capillary-like structures (Fig. 6c, left), whereas miR-
200b-3p-inhibited supernatants increased the capacity when compared to control (Fig. 6c, right). These data 
suggest that hepatic miR-200b-3p downregulates angiogenic capability of HUVECs.
Table 1.  Cases for the enrolled HCC patients. Tumour stage, tumour grade and growth pattern are classified 
as according to WHO (2019) classification.
Case Age Sex Tumor stage Growth pattern Tumor grade Cirrhosis
1 65 M 1b Mixed Moderate −
2 71 M 1a Trabecular Well −
3 75 F 1b Pseudoglandular Moderate +
4 68 F 1b Mixed Poor −
5 73 M 1b Trabecular Well −
6 69 F 1b Trabecular Moderate +
7 56 M 1a Trabecular Moderate −
8 79 M 1b Mixed Moderate +
9 61 M 2 Trabecular Poor −
10 74 M 1a Solid Moderate +
11 79 M 2 Mixed Moderate −
12 55 M 1a Trabecular Well +
13 82 F 2 Trabecular Moderate −
14 52 M 1a Trabecular Moderate +
15 71 M 1b Mixed Moderate −
16 66 M 2 Mixed Well +
17 62 M 1a Trabecular Moderate +
18 62 F 2 Trabecular Moderate −
19 64 F 2 Trabecular Well +
20 68 M 2 Mixed Moderate −
21 59 M 1a Pseudoglandular Moderate −
22 73 M 2 Trabecular Moderate −
23 61 F 1a Mixed Well +
24 63 M 1a Pseudoglandular Well −
25 73 F 1b Mixed Moderate −
26 70 M 1b Mixed Moderate −
27 70 M 1a Trabecular Moderate −
28 69 M 1a Trabecular Moderate +
29 60 F 1a Trabecular Well +
30 62 M 1b Trabecular Moderate −
31 57 M 1b Mixed Moderate −
32 74 F 1a Trabecular Well −
33 61 M 1b Mixed Moderate −
34 64 F 1a Trabecular Well +
35 57 F 1b Solid Poor −
36 55 M 1b Trabecular Poor +
37 69 M 1b Mixed Moderate −
38 50 M 2 Trabecular Moderate +
39 77 F 2 Mixed Moderate −
40 69 F 1a Trabecular Moderate +
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miR‑200b‑3p is transferred by exosomes. Exosomes are a heterogeneous population of vesicles that 
originate from cells. Exosomes play a key role in the intercellular communication between cancer cells and 
stroma  cells17,18. Hence, we examined if exosomes released from cancer cells could transfer miR-200b-3p to 
endothelial cells. Exosomes were isolated from HCC cell lines and expression levels of miR-200b-3p in exosomes 
were measured. The expression levels of miR-200b-3p in the exosomes were high in Hep3B cells and low in HLE 
cells (Fig. 7a), which were proportional to those detected in cells (Fig. 1c). Next, HUVECs were cultured with 
exosomes isolated from HLE cell culture supernatants and expression levels of ERG in HUVECs were measured. 
As shown in Fig. 7b, addition of exosomes suppressed the expression of ERG in HUVECs as compared with 
control (no exosomes). To confirm the role of exosome-associated miR-200b-3p in inhibition of ERG expression 
in HUVECs, we overexpressed miR-200b-3p in HLE cells, and exosomes were isolated from miR-200b-3p-over-
expressing HLE cell culture supernatants (Fig. 7c). Exosomes isolated from miR-200b-3p-overexpressing HLE 
cell culture medium significantly reduced ERG expression in HUVECs when compared to control (Fig. 7d). 
These data suggest that miR-200b-3p is transferred via exosomes from hepatocytes to endothelial cells, resulting 
in suppression of endothelial ERG expression.
Discussion
Angiogenesis is necessary for cancer growth and metastasis and regulated by various molecules. In this study, 
we investigated the role of miR-200b-3p in regulating cancer angiogenesis in HCC. We used 40 paired human 
HCC tissues and adjacent non-cancer liver tissues and examined the expression of miR-200b-3p. We used 
Taqman advanced miRNA cDNA synthesis kit and a pair of advanced miRNA control to avoid amplification 
bias and reflect true expression level of mature miRNA. miR-200b is known decreased in hepatocellular carci-
noma (HCC)19,20. In the present study, we focused on miR-200b-3p, which originates from pre-miR-200b. Our 
results demonstrated that clinical HCC specimens exhibited lower expression levels of miR-200b-3p than the 
surrounding non-cancer liver tissues. Interestingly, this lower expression of miR-200b-3p was associated with 
poor tumor differentiation, especially in HCC with trabecular pattern. Since miR-200b-3p is reported to inhibit 
 angiogenesis9,10,21,22, we hypothesized that downregulation of miR-200b-3p in cancer cells may drive blood ves-
sel hyperplasia in HCC.
miR-200b and other miR-200 family members (miR-200a/429) are reported to be ERG targeting miRNAs 
in prostate  cancer23 and are involved in promoting cancer growth and invasion. ERG is an essential regulator of 
Figure 1.  Expression level of miR-200b-3p in HCC tissues and cell lines. (a) The expression levels of miR-
200b-3p in 40 pairs of HCC and adjacent non-cancer tissues were evaluated by qRT-PCR. ***p < 0.0001. (b) 
The expression levels of miR-200b-3p in the well (10 cases), moderately (26 cases), and poorly differentiated (4 
cases) HCC groups were measured. (c) miR-200b-3p expression levels in HCC cell lines (Hep3B, HepG2, and 
HLE cells) and human umbilical vein endothelial cells (HUVECs) were quantitated. ***p < 0.0001.
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Characteristics Number of patients Percentage of patients (%) miR-200b-3p/miR-191-5p (mean ± SD) p value
Age (years)
0.344a> 70 26 65 0.293 ± 0.323
≤ 70 14 35 0.218 ± 0.171
Gender
0.409bMale 26 65 0.293 ± 0.235
Female 14 35 0.317 ± 0.352
Alcohol history
0.415bYes 19 47.5 0.228 ± 0.227
No 21 52.5 0.301 ± 0.321
Diabetes mellitus
0.185bYes 13 32.5 0.182 ± 0.209
No 27 67.5 0.308 ± 0.303
Performance status
0.219c
0 24 60 0.255 ± 0.247
1 11 27.5 0.203 ± 0.257
2 5 12.5 0.463 ± 0.431
Child Pugh score
0.124c
1 31 77.5 0.221 ± 0.231
2 3 7.5 0.511 ± 0.354
3 6 15 0.382 ± 0.417
Liver transferase (IU/L)
0.354bLow (AST ≤ 30 or ALT ≤ 25) 17 42.5 0.223 ± 0.162
High (AST > 30 or ALT > 25) 23 57.5 0.299 ± 0.342
AFP (ng/mL)
0.176b≤ 10 22 55 0.212 ± 0.223
> 10 18 45 0.333 ± 0.330
Platelets (× 104/µL)
0.346b≤ 16 23 57.5 0.303 ± 0.309
> 16 17 42.5 0.218 ± 0.234
Prothrombin time (s)
0.302b≤ 13 32 80 0.244 ± 0.249
> 13 8 20 0.359 ± 0.385
Viral infection
0.245aYes 29 72.5 0.289 ± 0.319
No 11 27.5 0.208 ± 0.117
Diameter (cm)
0.899b≤ 2 17 42.5 0.260 ± 0.312
> 2 23 57.5 0.272 ± 0.260
Multiplicity
0.082bYes 5 12.5 0.470 ± 0.311
No 35 87.5 0.238 ± 0.267
Differentiation
0.447c
Well 10 25 0.358 ± 0.375
Moderate 26 65 0.246 ± 0.250
Poor 4 10 0.173 ± 0.174
Pattern
0.401c
Trabecular 21 52.5 0.314 ± 0.312
Solid 2 5 0.087 ± 0.097
Pseudoglandular 3 7.5 0.064 ± 0.053
Mixed 14 35 0.264 ± 0.256
Differentiation in trabecular
0.081bWell 7 33.3 0.482 ± 0.387
Moderate + poor 14 66.7 0.230 ± 0.240
Continued
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Table 2.  The relationship between miR-200b-3p expression levels in cancer tissues and clinicopathological 
factors of patients with HCC. AFP, α-fetoprotein, BCLC Barcelona Clinic Liver Cancer. Statistical analyses: 
aunpaired t test with Welch’s correction, bunpaired t test, cone-way analysis of variance, dKruskal–Wallis test.
Characteristics Number of patients Percentage of patients (%) miR-200b-3p/miR-191-5p (mean ± SD) p value
Grade in mixed
0.352bWell 2 14.3 0.101 ± 0.043
Moderate + poor 12 85.7 0.291 ± 0.268
Microvascular invasion
0.512aYes 6 15 0.437 ± 0.437
No 34 85 0.247 ± 0.247
Cirrhosis
0.381bYes 16 40 0.315 ± 0.340
No 24 60 0.235 ± 0.233
TNM stage
0.511bI 29 72.5 0.248 ± 0.276
II 11 27.5 0.315 ± 0.295
BCLC stage
0.540d
0 4 10 0.204 ± 0.095
A 16 40 0.257 ± 0.270
B 1 2.5 0.682 ± 0.000
C 13 32.5 0.212 ± 0.250
D 6 15 0.382 ± 0.417
Figure 2.  ERG-positive endothelial cells in HCC tissues. (a) Representative images of ERG-positive cells in 
a patient with moderately differentiated HCC. Arrowheads indicate positive staining of ERG in the nuclei of 
endothelial cells (scale bar, 50 μm). (b) The numbers of ERG-positive cells in the 40 pairs of non-cancer and 
cancer tissues from patients with HCC. ***p < 0.0001. (c) The number of ERG positive endothelial cells showed a 
negative correlation with the expression of miR-200b-3p in the HCC tissues (r = − 0.4836, p < 0.0001).
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Figure 3.  miR-200b-3p negatively regulates ERG expression in HUVECs. ERG protein expression in the 
HUVECs was analyzed by Western blotting. (a) miR-200b-3p was overexpressed in the HUVECs using an 
overexpression plasmid. miRNA control plasmid was used as a control. (b) miR-200b-3p was inhibited by 
miR-200b-3p inhibitor. miRNA inhibitor negative control was used as a control. Upper panel, representative 
immunoblot data from three independent analyses of HUVEC lysates. Lower panel, quantitative data are shown. 
*p < 0.01, **p < 0.001.
Figure 4.  ERG is a direct target of miR-200b-3p. (a) The complementary sequences of miR-200b-3p in the ERG 
mRNA 3′-UTR. (b) Luciferase activity after transfection with constructs containing the ERG mRNA 3′-UTR 
(wild-type or mutant type) with or without miR-200b-3p expression plasmid was evaluated using dual-luciferase 
reporter system. *p < 0.01, **p < 0.001, ***p < 0.0001.
8Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:10418  | https://doi.org/10.1038/s41598-020-67425-4
www.nature.com/scientificreports/
endothelial homeostasis and tumor  angiogenesis24, but there is no study about ERG as miRNA-200b-3p target. 
In this study, we demonstrated that ERG is a miR-200b-3p target. The numbers of ERG positive endothelial cells 
in highly vascular cancer tissues were upregulated when compared to those in non-cancer tissues. Our in vitro 
experiments manipulating miR-200b-3p expression revealed that the decreased levels of miR-200b-3p in HCC 
tissues drive ERG expression in HUVECs. We know from the literature that angiogenesis in cancer tissues is 
regulated by various molecules. Among them, our data suggest that decreased levels of miR-200b-3p in cancer 
hepatocytes partly contribute to angiogenesis in HCC tissues.
Cancer cells are known to release large numbers of exosomes, which deliver molecules that have a patho-
genic role in cancer  pathology25,26. Exosomes are heterogeneous membrane-enclosed structures released by 
cells. Exosomes mediate both autocrine and paracrine signal transduction by transferring proteins, RNA, and 
 miRNAs27,28. Recent evidence indicates that exosomes promote HCC cell proliferation, growth, invasion, and 
metastasis, as well as the development of drug  resistance29. In this study, we demonstrated evidence that miR-
200b-3p is released from hepatocytes inside exosomes and transferred to endothelial cells. Although we did not 
quantify levels of exosomes from non-tumor and tumor hepatocytes, the expression levels of miR-200b-3p in 
cancer area were quite lower than those in non-cancer area. It is likely that lower expression levels of exosomal 
miR-200b-3p is due to decreased expression of miR-200b-3p in HCC cells.
Figure 5.  Hepatic miR-200b-3p suppresses ERG expression in HUVECs. (a) miR-200b-3p was overexpressed 
in HLE cells using an overexpression plasmid and relative expression of miR-200b-3p was measured. HLE cells 
transfected with control plasmid were used as a control. (b) miR-200b-3p was inhibited using miR-200b-3p 
inhibitor in the Hep3B cells and relative expression of miR-200b-3p was measured. Hep3B cells transfected with 
miRNA inhibitor negative control were used as a control. (c) HUVECs were cultured in the presence of culture 
supernatants of miR-200b-3p-overexpressing HLE cells or control medium transfected with miRNA control 
plasmid. Upper panel, representative immunoblot data from three independent analyses of HUVEC lysates. 
Lower panel, relative expression of ERG. (d) HUVECs were cultured in the presence of culture supernatants 
of miR-200b-3p-inhibited Hep3B cells or control medium transfected with miRNA inhibitor negative control. 
Upper panel, representative immunoblot data from three independent analyses of HUVEC lysates. Lower panel, 
relative expression of ERG. #p < 0.05, *p < 0.01, **p < 0.001.
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Our data indicate that hepatocyte-derived miR-200b-3p inhibits ERG expression in HUVECs. However, 
its effect was partial as assessed by overexpression or inhibition of miR-200b-3p. Although ERG is a target of 
miR-200b-3p in endothelial cells, a single transcript may be regulated by multiple miRNAs, as each miRNA is 
known to regulates hundreds of genes. For instance, miR-196a and miR-196b induced ERG downregulation in 
 leukemia30. ERG is a target of miR-145 in colorectal cancer and prostate  cancer12,31. Alternatively, angiogenic 
growth factors, including vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), 
and fibroblast growth factor (FGF), released from HCC  cells32 may affect ERG expression in HUVECs. Thus, 
ERG expression in endothelial cells is regulated by multiple mechanisms and a single inhibition of miR-200b-3p 
has a limited effect. Regulation of ERG by miRNA-200b-3p in other cancers is a subject for future investigation.
In this study, we did not evaluate the mechanisms underlying the downregulation of miR-200b-3p in HCC 
cells. Recent studies have revealed an importance of epigenetic control in the expression of distinct miRNAs. The 
expression of the miR-200 family is reported to be regulated by DNA methylation and histone  modifications33. 
The promoter methylation status of miR-200b is reported to determine tumor outcome in gastric  cancer34. The 
hypo-methylated promoter enhances miR-200b expression in pancreas  cancer35. Methylation-specific PCR (MSP) 
and bisulfite sequencing PCR (BSP) revealed that CpG sites in the promoter region of microRNA-200b were 
extensively methylated in HCC cells with concomitant downregulation of microRNA-200b  expression8. Thus, 
epigenetic control appears to be important in the regulation of miR-200b-3p expression in HCC cells. Alterna-
tively, cancer microenvironment including hypoxia may affect miR-200b-3p expression. Previous studies have 
reported various miRNAs that are differentially expressed in response to hypoxia, among which miR-200b was 
Figure 6.  Hepatic miR-200b-3p inhibits angiogenic capability of HUVECs. (a) Wounds were generated by 
scratching with a sterile 200-µL tip. The HUVECs were cultured for 24 h with culture supernatants of miR-200b-
3p-overexpression (upper left), miR-200b-3p-inhibitition (lower left), transfected with miRNA control plasmid 
or miRNA inhibitor negative control, respectively. Representative images of wound healing assay were shown 
at indicated time after scratch. Right, wound distance at different time points was measured and presented as 
the percentage of wound closure at time 0. (b) The HUVECs were cultured with culture supernatants of miR-
200b-3p-overexpression (upper), miR-200b-3p-inhibition (lower) for 24 h and cell proliferation was assessed 
by XTT assay. (c) The HUVECs were seeded on Matrigel-coated plates and cultured with culture supernatants 
of miR-200b-3p-overexpression (left), miR-200b-3p-inhibitition (right). Shown are representative images of 
tube formation after 6 h (scale bar, 200 μm). Experiments were performed in triplicates. #p < 0.05, *p < 0.01, 
**p < 0.001, ***p < 0.0001.
10
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:10418  | https://doi.org/10.1038/s41598-020-67425-4
www.nature.com/scientificreports/
reported to be  downregulated36. Further studies are necessary to understand the precise mechanisms underlying 
downregulation of miR-200b-3p in HCC cells.
The results of our study are illustrated in Fig. 8. In non-tumor tissues, exosomal miR-200b-3p released from 
hepatocytes downregulates vascular proliferation by inhibiting ERG expression in endothelial cells. By contrast, 
miR-200b-3p expression in HCC cells is downregulated, which drives vascular proliferation by enhancing ERG 
expression in endothelial cells. Hence, miR-200b-3p may be a novel molecular target for the treatment of HCC.
Method
Human tissue samples. In this study, we employed 40 pairs of tumor and adjacent non-tumor tissue 
derived from patients with HCC, who underwent surgical resection between January 2015 and December 2016 
at Okayama University Hospital. The patients who underwent chemotherapy or radiotherapy before the resec-
tion were not included in this study. All the hematoxylin and eosin-stained tumor glass slides used for diagnosis 
were reviewed and the degree of differentiation of cancer was recorded. One representative tumor slide was 
Figure 7.  miR-200b-3p is transferred via exosomes. (a) Exosomes were isolated from the HCC cell lines and 
the expression levels of miR-200b-3p in the exosomes were measured. (b) HUVECs were cultured with or 
without exosomes isolated from HLE cell culture supernatants, and the ERG expression levels in HUVECs were 
investigated by Western blotting. Upper panel, representative immunoblot data from three independent analyses 
of HUVEC lysates. Lower panel, relative expression of ERG. (c) HLE cells were transfected with miR-200b-3p 
overexpression plasmid or control plasmid and the exosomes were isolated from the culture supernatants. 
miR-200b-3p expression levels in the exosomes were quantified by qRT-PCR. (d) HUVECs were cultured with 
exosomes isolated from miR-200b-3p-overexpressing HLE cell culture supernatants, and the ERG expression 
levels in HUVECs were investigated by Western blotting. Culture supernatants from HLE cells transfected with 
control plasmid were used as a control. Upper panel, representative immunoblot data from three independent 
analyses of HUVEC lysates. Lower panel, relative expression of ERG. *p < 0.01, **p < 0.001, ***p < 0.0001.
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selected for each case and the block was used for immunohistochemical studies. The protocol in this study was 
reviewed and approved by the Ethics Committee of Okayama University (1703-007). Although individual written 
consents were not obtained, we disclosed the study plan on our website, providing the patients or their families 
with the opportunity to opt out, and only the cases without their refusal were enrolled in the study. This consent 
procedure conformed to amended Ethical Guidelines for Clinical Studies provided by Ministry of Health, Labor 
and Welfare of Japan (May 31, 2015) and was approved by the institutional review boards. All methods were 
performed in accordance with the relevant guidelines and regulations.
Cell culture. Hep3B cells (DS Pharma Biomedical, Osaka, Japan) were cultured in Eagle’s minimal essential 
medium (MEM) (Sigma-Aldrich, St. Louis, MO, USA) supplemented with MEM non-essential amino acid solu-
tion, 10% fetal bovine serum (FBS) (HyClone, UT, USA), 100 U/mL penicillin, and 100 μg/mL streptomycin 
(Sigma-Aldrich). HepG2 and HLE cells (JCRB cell bank, Osaka, Japan) were cultured in Dulbecco’s modified 
Eagle medium (Nacalai Tesque, Kyoto, Japan) supplemented with 10% FBS, 100 U/mL penicillin and 100 μg/mL 
streptomycin. Human umbilical vein endothelial cells (HUVECs) (Takara Bio Inc, Shiga, Japan) were cultured 
in EndoGRO™-VEGF Complete medium (Millipore, NJ, USA) in the absence of antibiotics. All cell lines were 
incubated at 37 °C and 5%  CO2 in a humidified incubator.
Transfection. Transfection was performed using Lipofectamine 3000 or Lipofectamine RNAiMax (Life 
Technologies, Carlsbad, CA, USA) in OPTI-MEM 1X reduced serum medium (Gibco, MD, USA) for 48  h. 
For gain-of-function analysis, 2.5 µg of precursor miR-200b-3p expression plasmid (HmiR0001-MR04, Gene-
Copoeia, MD, USA) or precursor miRNA scrambled control plasmid (CmiR0001-MR04, GeneCopoeia) was 
used for HUVECs and HLE cells (native miR-200b-3p expression; low) in 6-well plate. For loss-of-function 
experiments, 200 pmol mirVana hsa-miR-200b-3p inhibitor (4464084, Ambion, TX, USA) or 40 pmol mirVana 
miRNA inhibitor Negative Control #1 (4464076, Ambion) was introduced into the HUVECs and Hep3B cells 
(native miR-200b-3p expression; high) cultured in 6-well plate.
Preparation of culture supernatants. miR-200b-3p-overexpressing HLE cells and miR-200b-3p-inhib-
ited Hep3B cells were cultured for 48  h. Culture supernatants were harvested and centrifuged at 2,000g for 
10 min at 4 °C, and the resultant clear culture supernatants were stored at − 80 °C until use.
Quantitative real‑time PCR (qRT‑PCR) of miRNAs. Total RNA was extracted from human formalin-
fixed paraffin-embedded (FFPE) tissues, cell lines, and exosomes using the RecoverAll™ Total Nucleic Acid Iso-
lation Kit (Invitrogen, CA, USA), mirVana™ miRNA Isolation Kit (Invitrogen), and Total Exosome RNA and 
Protein Isolation Kit (Invitrogen), respectively, following the manufacturer’s instructions. cDNA was synthe-
sized from total RNA using TaqMan Advanced miRNA cDNA Synthesis kit (Applied Biosystems, Foster City, 
CA, USA). qRT-PCR analysis was performed on StepOnePlus real-time PCR system with TaqMan advanced 
miRNA assays (Applied Biosystems). To detect miR-200b-3p expression, hsa-miR-200b-3p (477963-mir) was 
used as the primer. According to the manufacturer’s instructions, a set of controls, miR-191-5p (477952-mir)37 
and miR-26a-5p (477995-mir), was used to validate the expression levels of miR-200b-3p from FFPE tissues 
and cell lines. miRNAs including miR-191-5p and miR-26a-5p were statistically superior to the most commonly 
used reference RNAs used in miRNA qRT-PCR experiments, such as 5S rRNA, U6 snRNA, or total  RNA38. The 
Figure 8.  A schematic illustration indicating the role of miR-200b-3p in angiogenesis in HCC tissues. Left 
panel: In non-cancer tissues, hepatocytes generate and release miR-200b-3p via exosomes, which inhibits ERG 
protein expression in endothelial cells. Decreased expression of ERG inhibits the proliferation of endothelial 
cells. Right panel: In HCC tissues, miR-200b-3p expression by HCC cells is suppressed, and the ERG expression 
in endothelial cells is no longer inhibited. As a result, ERG expression is augmented, and angiogenesis is 
increased in HCC tissues.
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relative expression levels validated by miR-191-5p and miR-26a-5p were constantly similar (not shown). There-
fore, we have shown the expression data relative to miR-191-5p. miR-200b-3p expression in the exosomes was 
normalized using 1 µL of 1 pM spike-in control, ath-miR-159a (478411-mir). All primers were purchased from 
Applied Biosystems. All experiments were performed in triplicates and the relative expression was calculated 
using the ∆∆CT method.
Immunohistochemistry. Immunostaining was performed using the Histofine Simple Stain MAX-PO 
(Nichirei Biosciences Inc, Tokyo, Japan), following the manufacturer’s instructions. Briefly, the sections (4 µm 
slices) were deparaffinized, rehydrated, and subjected to heat-induced epitope retrieval in 0.5 M EDTA buffer 
(pH 8.0). Next, the sections were treated with 0.3%  H2O2 in methanol and incubated with rabbit monoclonal 
anti-ERG antibody (1:1) (Histofine, Tokyo, Japan) for 90 min at room temperature. The sections were rinsed 
and incubated with peroxidase-conjugated secondary antibodies at room temperature for 45 min. Diaminoben-
zidine (DAKO, Carpinteria, CA, USA) was used as a chromogen. The images of four random consecutive areas 
(each area, 371 µm3) were captured under 20 × magnification of a light microscope. The number of ERG-positive 
nuclei in the endothelial cells was counted using the Image J software.
Dual‑luciferase reporter assay. HEK 293T cells (ATCC, VA, USA) were seeded in 12-well plates and cul-
tured in DMEM supplemented with 10% FBS and antibiotics until the cells reached approximately 80% conflu-
ency. Synthetic oligonucleotides of 23 base pairs containing miR-200b-3p binding sequence were designated as 
wild type ERG 3′-UTR (Thermo Fisher Scientific, MA, USA), which was cloned into the pmirGLO Dual-Lucif-
erase miRNA Target Expression Vector (Promega, WI, USA) at XbaI restriction enzyme site. Mutant type ERG 
3′-UTR constructs were also generated by replacing the targeting site of seed region with thymine (T) (Thermo 
Fisher Scientific). HEK 293 T cells were transiently co-transfected with 50 ng of luciferase reporter construct 
(empty vector as control or ERG wild type or ERG mutant type) along with 1 µg of precursor miRNA-200b-3p 
expression plasmid or precursor miRNA scrambled control plasmid using Lipofectamine 3000, following the 
manufacturer’s instructions. Each sample was cultured in duplicates for 48 h. The cell lysates were harvested to 
determine the firefly and Renilla luciferase activity using a Dual-Luciferase Reporter Assay System (Promega) 
with Fluoroskan Ascent FL (Thermo Fisher Scientific). The luminescence value was normalized by calculating 
the ratio of firefly luminescence to Renilla luminescence. Three independent experiments were performed.
Isolation of exosomes. Confluent cells were washed with phosphate buffer saline (PBS) twice and cultured 
in serum-free medium for 24 h. The culture media were collected and centrifuged at 2000g and 4 °C for 10 min. 
Supernatant was filtered through a 0.2-µm syringe filter. The exosomes were isolated using the Total Exosome 
Isolation kit (from cell culture media) (Thermo Fisher Scientific), following the manufacturer’s instructions. 
Briefly, 0.5 volumes of the Total Exosome Isolation reagent were mixed with the culture supernatant and incu-
bated at 4  °C overnight. The samples were centrifuged at 10,000g and 4  °C for 1 h and the supernatant was 
discarded. The pellets were resuspended in D-PBS(–) for HUVEC culture or Exosome Resuspension Buffer 
(Thermo Fisher Scientific) for isolation of miR-200b-3p.
Western blotting. The cells were lysed in RIPA buffer containing protease inhibitor. The total protein con-
centrations were measured using the BCA Protein Assay Kit (TaKaRa). Equal amounts of lysates were loaded 
per lane on 4–12% polyacrylamide gels (Thermo Fisher Scientific). The proteins were resolved by sodium dode-
cyl sulfate (SDS)-polyacrylamide gel electrophoresis. The resolved proteins were transferred onto nitrocellu-
lose membranes (pore size, 0.45 µm). The membrane was incubated with anti-ERG antibody (1:10) or anti-
GAPDH antibody (1:5,000) (Cell Signaling, MA, USA) overnight. Next, the membrane was incubated with 
the horseradish peroxidase-conjugated rabbit IgG antibody (1:1,000) (Cell Signaling, MA, USA). The proteins 
were visualized using the enhanced chemiluminescence detection reagents (ImmunoStar LD; FUJIFILM Wako, 
Osaka, Japan). The protein band intensity was quantified using Image Studio Lite software. All experiments were 
repeated in triplicates.
Scratch wound healing assay. The HUVECs were seeded in a 6-well plate to obtain the confluent mon-
olayer. The wounds were generated by scratching the monolayer with a sterile 200-µL tip. The wounded cell 
monolayers were cultured for 24 h. The wound distance at different time points was measured by Image J soft-
ware and presented as the percentage of wound closure at time 0. The experiments were performed in triplicates.
Proliferation assay. HUVECs were cultured in 96-well plate for 24 h. 50 µL of XTT labeling mixture (final 
XTT concentration 0.3 mg/mL, Cell proliferation Kit II, Sigma-Aldrich) was added into each well. After incu-
bation at 37 °C for 1 h, the absorbance of each well was measured at 480–650 nm by using ELISA reader. Each 
sample was tested in duplicates, and the experiments were performed in triplicates.
Tube formation assay. The HUVECs were starved for 6  h in Medium 200 Phenol Red Free medium 
(Gibco). The cells (4 × 104/well) were seeded onto the 24-well plate precoated with Matrigel Basement Mem-
brane Matrix (Corning, NY, USA) and incubated with culture supernatants containing 1% FBS for 6 h. Next, 
the cells were incubated with 2 μg/mL Calcein (Invitrogen) for 30 min. The tube formation was visualized and 
photographed using the BZ-X700 fluorescence microscope (Keyence Corp, Osaka, Japan). The total tube length 
was measured by cellSens standard under 10X magnification. Each treatment was performed in triplicates, and 
4 visions were counted to obtain an average.
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Statistical analysis. The data were analyzed using the GraphPad Prism software (GraphPad Software, 
San Diego, CA, USA). Student t test was used to determine the statistical significance. Data are presented as 
mean ± standard error of mean (SEM). The relation between the miR-200b-3p expression and number of ERG 
positive cells in HCC tissues was assessed by using the Pearson’ s relation coefficient. Clinical data were analysed 
by unpaired t test, unpaired t test with Welch’s correction, one-way analysis of variance, and Kruskal–Wallis test. 
The difference was considered statistically significant when the p value was less than 0.05 for all experiments.
Received: 22 February 2020; Accepted: 3 June 2020
References
 1. Bertuccio, P. et al. Global trends and predictions in hepatocellular carcinoma mortality. J. Hepatol. 67, 302–309 (2017).
 2. Bergers, G. & Benjamin, L. E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3, 401–410 (2003).
 3. Gacche, R. N. & Meshram, R. J. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents 
arresting tumor growth. Prog. Biophys. Mol. Biol. 113, 333–354 (2013).
 4. Bracken, C. P., Scott, H. S. & Goodall, G. J. A network-biology perspective of microRNA function and dysfunction in cancer. Nat. 
Rev. Genet. 17, 719–732 (2016).
 5. Iwakawa, H. O. & Tomari, Y. The functions of microRNAs: mRNA decay and translational repression. Trends Cell Biol. 25, 651–665 
(2015).
 6. Wang, W., Zhang, E. & Lin, C. MicroRNAs in tumor angiogenesis. Life Sci. 136, 28–35 (2015).
 7. Xu, X. et al. The role of microRNAs in hepatocellular carcinoma. J. Cancer 9, 3557–3569 (2018).
 8. Wu, W. R. et al. Methylation-associated silencing of miR-200b facilitates human hepatocellular carcinoma progression by directly 
targeting BMI1. Oncotarget 7, 18684–18693 (2016).
 9. Chan, Y. C., Roy, S., Khanna, S. & Sen, C. K. Downregulation of endothelial microRNA-200b supports cutaneous wound angio-
genesis by desilencing GATA binding protein 2 and vascular endothelial growth factor receptor 2. Arterioscler. Thromb. Vasc. Biol. 
32, 1372–1382 (2012).
 10. Pecot, C. V. et al. Tumour angiogenesis regulation by the miR-200 family. Nat. Commun. 4, 2427 (2013).
 11. Sinha, M., Ghatak, S., Roy, S. & Sen, C. K. microRNA-200b as a switch for inducible adult angiogenesis. Antioxid. Redox Signal. 
22, 1257–1272 (2015).
 12. Li, S. et al. miR-145 suppresses colorectal cancer cell migration and invasion by targeting an ETS-related gene. Oncol. Rep. 36, 
1917–1926 (2016).
 13. Wang, M., Gao, W., Lu, D. & Teng, L. MiR-1271 inhibits cell growth in prostate cancer by targeting ERG. Pathol. Oncol. Res. 24, 
385–391 (2018).
 14. Birdsey, G. M. et al. Transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin. Blood 111, 
3498–3506 (2008).
 15. Shah, A. V., Birdsey, G. M. & Randi, A. M. Regulation of endothelial homeostasis, vascular development and angiogenesis by the 
transcription factor ERG. Vascul. Pharmacol. 86, 3–13 (2016).
 16. Shah, A. V. et al. The endothelial transcription factor ERG mediates Angiopoietin-1-dependent control of Notch signalling and 
vascular stability. Nat. Commun. 8, 16002 (2017).
 17. Jabalee, J., Towle, R. & Garnis, C. The role of extracellular vesicles in cancer: cargo, function, and therapeutic implications. Cells 
7, 93 (2018).
 18. Lane, R. E., Korbie, D., Hill, M. M. & Trau, M. Extracellular vesicles as circulating cancer biomarkers: opportunities and challenges. 
Clin. Transl. Med. 7, 14 (2018).
 19. Dhayat, S. A. et al. The microRNA-200 family—a potential diagnostic marker in hepatocellular carcinoma. J. Surg. Oncol. 110, 
430–438 (2014).
 20. Hung, C. S. et al. MicroRNA-200a and -200b mediated hepatocellular carcinoma cell migration through the epithelial to mesen-
chymal transition markers. Ann. Surg. Oncol. 20(Suppl 3), S360–S368 (2013).
 21. Choi, Y. C., Yoon, S., Jeong, Y., Yoon, J. & Baek, K. Regulation of vascular endothelial growth factor signaling by miR-200b. Mol. 
Cells 32, 77–82 (2011).
 22. Williams, L. V., Veliceasa, D., Vinokour, E. & Volpert, O. V. miR-200b inhibits prostate cancer EMT, growth and metastasis. PLoS 
ONE 8, e83991 (2013).
 23. Zhang, Z. et al. The tumor suppressive miR-200b subfamily is an ERG target gene in human prostate tumors. Oncotarget 7, 
37993–38003 (2016).
 24. Kalna, V. et al. The transcription factor ERG regulates super-enhancers associated with an endothelial-specific gene expression 
program. Circ. Res. 124, 1337–1349 (2019).
 25. Logozzi, M., Spugnini, E., Mizzoni, D., Di Raimo, R. & Fais, S. Extracellular acidity and increased exosome release as key pheno-
types of malignant tumors. Cancer Metastasis Rev. 38, 93–101 (2019).
 26. Spugnini, E. P., Logozzi, M., Di Raimo, R., Mizzoni, D. & Fais, S. A role of tumor-released exosomes in paracrine dissemination 
and metastasis. Int. J. Mol. Sci. https ://doi.org/10.3390/ijms1 91239 68 (2018).
 27. Gangoda, L., Boukouris, S., Liem, M., Kalra, H. & Mathivanan, S. Extracellular vesicles including exosomes are mediators of signal 
transduction: are they protective or pathogenic. Proteomics 15, 260–271 (2015).
 28. Wang, M. et al. Emerging function and clinical values of exosomal microRNAs in cancer. Mol. Ther. Nucleic Acids 16, 791–804 
(2019).
 29. Chen, R., Xu, X., Tao, Y., Qian, Z. & Yu, Y. Exosomes in hepatocellular carcinoma: a new horizon. Cell Commun. Signal 17, 1 (2019).
 30. Coskun, E. et al. The role of microRNA-196a and microRNA-196b as ERG regulators in acute myeloid leukemia and acute 
T-lymphoblastic leukemia. Leuk. Res. 35, 208–213 (2011).
 31. Hart, M. et al. The proto-oncogene ERG is a target of microRNA miR-145 in prostate cancer. FEBS J. 280, 2105–2116 (2013).
 32. Morse, M. A. et al. The role of angiogenesis in hepatocellular carcinoma. Clin. Cancer Res. 25, 912–920 (2019).
 33. Lim, Y. Y. et al. Epigenetic modulation of the miR-200 family is associated with transition to a breast cancer stem-cell-like state. J. 
Cell Sci. 126, 2256–2266 (2013).
 34. Kurashige, J. et al. Epigenetic modulation and repression of miR-200b by cancer-associated fibroblasts contribute to cancer inva-
sion and peritoneal dissemination in gastric cancer. Carcinogenesis 36, 133–141 (2015).
 35. Li, A. et al. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with 
elevated circulating miR-200a and miR-200b levels. Cancer Res. 70, 5226–5237 (2010).
 36. Chan, Y. C., Khanna, S., Roy, S. & Sen, C. K. miR-200b targets Ets-1 and is down-regulated by hypoxia to induce angiogenic 
response of endothelial cells. J. Biol. Chem. 286, 2047–2056 (2011).
 37. Grenda, A. et al. MicroRNAs aid the assessment of programmed death ligand 1 expression in patients with non-small cell lung 
cancer. Oncol Lett. 17, 5193–5200 (2019).
14
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:10418  | https://doi.org/10.1038/s41598-020-67425-4
www.nature.com/scientificreports/
 38. Peltier, H. J. & Latham, G. J. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable 
reference RNA targets in normal and cancerous human solid tissues. RNA 14, 844–852 (2008).
Author contributions
A.M.M.A. and A.M. planned experiments and wrote the manuscript. A.M.M.A., S.I., and H.K. performed experi-
ments and discussed the experimental findings and interpreted the results. M.F., T.O., Y.O. collected clinical 
information from H.C.C. patients and analyzed the data. M.F., T.O., T.Y. discussed the interpretation of the 
results. All authors reviewed the manuscript.
Competing interests 
The authors declare no competing interests.
Additional information
Supplementary information  is available for this paper at https ://doi.org/10.1038/s4159 8-020-67425 -4.
Correspondence and requests for materials should be addressed to A.M.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder. To view a copy of this license, visit http://creat iveco mmons .org/licen ses/by/4.0/.
© The Author(s) 2020
